索尔沃尼斯治疗选择SVN-114作为PTSD的主要候选人; Ilika PLC向医疗设备制造商提供了第一个商业固态电池电极. Solvonis Therapeutics picks SVN-114 as lead PTSD candidate; Ilika PLC ships first commercial solid-state battery electrodes to medical device maker.

溶剂治疗学选择SVN-114为PTSD治疗的主要候选者,此前的临床数据显示,对血清素、多巴胺和诺拉德雷纳受体进行了平衡的调制。 Solvonis Therapeutics has selected SVN-114 as its lead candidate for PTSD treatment, following preclinical data showing balanced modulation of serotonin, dopamine, and noradrenaline receptors. 该公司的目标是通过临床前开发来推进该化合物, 针对影响数百万人的疾病的未满足需求. The company aims to advance the compound through preclinical development, targeting unmet needs in a condition affecting millions. 与此同时,设在联合王国的Ilika PLC公司向医疗设备制造商Cirtec Medical公司交付了第一批商用Stereax固态电池电极,标志着该公司首次进行创收运输,是将其可移植医疗装置技术商业化的关键一步。 Meanwhile, UK-based Ilika PLC delivered its first commercial batch of Stereax solid-state battery electrodes to medical device manufacturer Cirtec Medical, marking its first revenue-generating shipment and a key step in commercializing its technology for implantable medical devices. 这一里程碑突出了用于保健应用的下一代电池开发工作取得的进展。 The milestone highlights progress in next-generation battery development for healthcare applications.